Selenoprotein gene variants, toenail selenium levels, and risk for advanced prostate cancer

Journal of the National Cancer Institute

Volumn 106, Issue 3, 2014, Pages

  Geybels, Milan S ^a   Van Den Brandt, Piet A ^a   Schouten, Leo J ^a   Van Schooten, Frederik J ^a   Van Breda, Simone G ^a   Rayman, Margaret P ^b   Green, Fiona R ^b   Verhage, Bas A J ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b UNIVERSITY OF SURREY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTATHIONE PEROXIDASE 1; SELENIUM; SELENOPROTEIN P; GLUTATHIONE PEROXIDASE; SELENOPROTEIN;

ADULT; ADVANCED CANCER; AGED; ANALYTICAL PARAMETERS; ARTICLE; COHORT ANALYSIS; DISEASE ASSOCIATION; GENE LINKAGE DISEQUILIBRIUM; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; SELENIUM BLOOD LEVEL; SINGLE NUCLEOTIDE POLYMORPHISM; TOENAIL SELENIUM LEVEL; CANCER STAGING; GENETIC PREDISPOSITION; GENETICS; METABOLISM; MIDDLE AGED; NAIL; NETHERLANDS; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; PROSTATE TUMOR; RISK; RISK ASSESSMENT; RISK FACTOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; COHORT STUDIES; GENETIC PREDISPOSITION TO DISEASE; GLUTATHIONE PEROXIDASE; HUMANS; MALE; MIDDLE AGED; NAILS; NEOPLASM STAGING; NETHERLANDS; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; SELENIUM; SELENOPROTEINS;

EID: 84898758946     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dju003     Document Type: Article

References (24)

1. Papp LV, Lu J, Holmgren A, Khanna KK. From selenium to selenoproteins: synthesis, identity, and their role in human health. Antioxid Redox Signal. 2007;9(7):775-806.
2. Hurst R, Hooper L, Norat T, et al. Selenium and prostate cancer: systematic review and meta-analysis. Am J Clin Nutr. 2012;96(1):111-122.
3. Peters U, Takata Y. Selenium and the prevention of prostate and colorectal cancer. Mol Nutr Food Res. 2008;52(11):1261-1272.
4. Duffield-Lillico AJ, Dalkin BL, Reid ME, et al. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU Int. 2003;91(7):608-612.
5. Klein EA, Thompson IM Jr, Tangen CM, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2011;306(14):1549-1556.
6. Nicastro HL, Dunn BK. Selenium and prostate cancer prevention: insights from the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Nutrients. 2013;5(4):1122-1148.
7. Rayman MP. Selenium and human health. Lancet. 2012;379(9822):1256-1268.
8. Meplan C, Hesketh J. Selenium and cancer: a story that should not be forgotten - insights from genomics. Cancer Treat Res. 2014;159:145-166.
9. Penney KL, Li H, Mucci LA, et al. Selenoprotein P genetic variants and mrna expression, circulating selenium, and prostate cancer risk and survival. Prostate. 2013;73(7):700-705.
10. Burk RF, Hill KE. Selenoprotein P - expression, functions, and roles in mammals. Biochim Biophys Acta. 2009;1790(11):1441-1447.
11. Brigelius-Flohe R, Kipp A. Glutathione peroxidases in different stages of carcinogenesis. Biochim Biophys Acta. 2009;1790(11):1555-1568.
12. Geybels MS, Verhage BA, van Schooten FJ, Goldbohm RA, van den Brandt PA. Advanced prostate cancer risk in relation to toenail selenium levels. J Natl Cancer Inst. 2013;105(18):1394-1401.
13. van den Brandt PA, Goldbohm RA, van 't Veer P, Volovics A, Hermus RJ, Sturmans F. A largescale prospective cohort study on diet and cancer in The Netherlands. J Clin Epidemiol. 1990;43(3):285-295.
14. van den Brandt PA, Schouten LJ, Goldbohm RA, Dorant E, Hunen PM. Development of a record linkage protocol for use in the Dutch Cancer Registry for epidemiological research. Int J Epidemiol. 1990;19(3):553-558.
15. Sobin L, Gospodarowicz M, Wittekind C, eds. TNM Classification of Malignant Tumors. 7th ed. Oxford: Wiley-Blackwell; 2009.
16. Carlson CS, Eberle MA, Rieder MJ, Yi Q, Kruglyak L, Nickerson DA. Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. Am J Hum Genet. 2004;74(1):106-120.
17. van Breda SG, Hogervorst JG, Schouten LJ, et al. Toenails: an easily accessible and longterm stable source of DNA for genetic analyses in large-scale epidemiological studies. Clin Chem. 2007;53(6):1168-1170.
18. van den Brandt PA, Goldbohm RA, van't Veer P, Bode P, Hermus RJ, Sturmans F. Predictors of toenail selenium levels in men and women. Cancer Epidemiol Biomarkers Prev. 1993;2(2):107-112.
19. Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994;81(3):515-526.
20. Barlow WE, Ichikawa L, Rosner D, Izumi S. Analysis of case-cohort designs. J Clin Epidemiol. 1999;52(12):1165-1172.
21. Lin DY, Wei LY. The robust inference for the Cox proportional hazards model. J Am Stat Assoc. 1989;84(408):1074-1078.
22. Geybels MS, Hutter CM, Kwon EM, et al. Variation in selenoenzyme genes and prostate cancer risk and survival. Prostate. 2013;73(7):734-742.
23. Bhatti P, Stewart PA, Hutchinson A, et al. Lead exposure, polymorphisms in genes related to oxidative stress, and risk of adult brain tumors. Cancer Epidemiol Biomarkers Prev. 2009;18(6):1841-1848.
24. Foster CB, Aswath K, Chanock SJ, McKay HF, Peters U. Polymorphism analysis of six selenoprotein genes: support for a selective sweep at the glutathione peroxidase 1 locus (3p21) in Asian populations. BMC Genet. 2006;7:56.